Boan Biotech (06955.HK) announced that the abibasip intraocular injection solution (“BA9101”) developed by the company has completed phase III clinical trials (clinical efficacy and safety comparison test) in China and plans to submit a marketing application.
Abbasip is a homologous dimeric glycoprotein formed by fusing the extracellular domain of human vascular endothelial growth factor receptor (VEGFR1Ig2 region and VEGFR2IG3 region) with the FC domain of human IgG1. It is a soluble inducing receptor that binds to VEGF-A, VEGF-B, and PlGF, and can inhibit the binding and activation of endogenous VEGF receptors with VEGF-A and PLGF, thereby treating pathological neovascularoid eye diseases of the retina and choroid.
Original Research Drug Alia(EYLEA) It was approved for marketing in the US and the European Union in 2011 and 2012, respectively. Currently approved indications include neovascularization (wet) age-related macular degeneration (NaMD), diabetic macular edema (DME), post-retinal vein occlusion (RVO), diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV), and retinopathy (ROP) in premature infants. AaliyahIt was approved for marketing in China in 2018, and the indications are NAMD and DME.